Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs
This cross-sectional study explores expenditures, negotiated pricing, and potential additional savings for top-selling cancer products in Medicare Part B and Part D.
Authors
- Thomas J. Hwang (ORCID: https://orcid.org/0000-0003-0717-1497)
- Ariadna Tibau
- Kerstin Noelle Vokinger
- Aaron S Kesselheim
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Zurich (CH)
- ETH Zurich (CH)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1001/jamahealthforum.2026.0509
- Primary Topic
- Healthcare Policy and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00